Allergan Adapts Trial Design; Latisse Endpoints Based On Consumer Feedback
Executive Summary
The clinical trial endpoints for Allergan's eyelash stimulant drug, Latisse, were determined through discussions with consumer panels about what was most desired in a drug that enhances eyelashes
You may also be interested in...
Allergan Bats Its Eyes At Consumers With Latisse Marketing Campaign
Allergan is charting new territory in marketing its eyelash growth stimulant Latisse, a product with a purely aesthetic indication that will be uniquely consumer-driven
Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.
King's CorVu Gets Reluctant "No" From Advisory Committee
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.